Noncontrolling Interest (Tables)

6 Months Ended

Jun. 30, 2023

Noncontrolling Interest [Abstract]

Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows:

	June 30, 2023
NCI – equity – December 31, 2022	$	20,615
Net loss attributable to NCI		(7,638	)
Impact of subsidiary equity transactions		(1,332	)
Lucid Diagnostics Inc. proceeds from issuance of preferred stock		13,625
Lucid Diagnostics Inc. proceeds from At-The-Market Facilities, net of deferred financing charges		284
Lucid Diagnostics Inc. issuance of common stock for settlement of APA-RDx installment and termination payment		713
Lucid Diagnostics Inc. issuance of common stock for settlement of vendor service agreement		147
Lucid Diagnostics Inc. Employee Stock Purchase Plan Purchase		276
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan		3,982
Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan		10
NCI – equity – June 30, 2023	$	30,682